Author details

Full Name

Peter Leif Bergsagel

Affiliation

ORCID

Career Start Year

1990

Papers

262

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37767768	Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.	Blood Cancer Discov	2024
37934799	ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.	Blood Cancer Discov	2024
37494698	Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.		2023
36226510	Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis.	American Journal of Hematology	2023
37961238	Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.		2023
37019896	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.	Blood Cancer J	2023
36878906	Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.		2023
37003846	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.	Clin Lymphoma Myeloma Leuk	2023
36928817	Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.	Nat Med	2023
36681151	Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.		2023
37230980	Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.		2023
36787254	Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant.		2023
35102148	A simple additive staging system for newly diagnosed multiple myeloma.	Blood Cancer Journal	2022
35705541	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.	Nat Commun	2022
35653112	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.	Blood Cancer Discov	2022
35650175	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.	Blood Cancer Journal	2022
36096078	Risk factors for severe infection and mortality inÂ COVID-19 and monoclonal gammopathy of undetermined significance.	Blood	2022
35646666	Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells.	Front Oncol	2022
35882836	Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms.	Blood Cancer J	2022
35694818	Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma.	British Journal of Haematology	2022
36001803	Genomic profiling for clinical decision making in lymphoid neoplasms.	Blood	2022
35743843	Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.	Life	2022
35737873	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.	Blood advances	2022
36424376	Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.	Blood Cancer Journal	2022
35251496	Transplantation of autologous bone marrow pre-loaded with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma.	Oncotarget	2022
35175355	Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.	Blood Adv	2022
35090171	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy inÂ multiple myeloma.	Blood	2022
34611479	Multipeptide stimulated PBMCs generate T/T for adoptive cell therapy in multiple myeloma.	Oncotarget	2021
34233962	The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.	Clin Cancer Res	2021
33742076	Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups.	NPJ Precis Oncol	2021
34107340	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.	Transplantation and Cellular Therapy	2021
33662288	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.	Lancet Oncol	2021
34258584	Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.	Blood Cancer Discov	2021
34088417	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.	Mayo Clin Proc	2021
32640012	Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.	Blood	2021
33406405	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma.	Cell Metab	2021
34732728	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.	Nat Commun	2021
31439945	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.	Leukemia	2020
31582538	Identification of PIKfyve kinase as a target in multiple myeloma.	Haematologica	2020
32179748	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias.	Blood Cancer J	2020
32442065	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.	J Clin Oncol	2020
32750129	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.	Blood advances	2020
32954360	Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.		2020
33008815	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.	Clinical Cancer Research	2020
32503975	Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity.	Leukemia	2020
32782240	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.	Blood Cancer Journal	2020
34661146	Promiscuous Structural Variants Drive Myeloma Initiation and Progression.		2020
30850386	Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.	Blood advances	2019
31844041	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.	Blood Cancer J	2019
30315229	Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.	Leukemia	2019